drugset / Trial / NCT02249130

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

NCT02249130

Phase 2 Completed 18 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To investigate the safety of a standard triple therapy regimen of delavirdine (DLV), zidovudine (ZDV), and lamivudine (3TC) following 14 days of experimental treatment with regimens of tipranavir (TPV) with and without ritonavir (RTV)

Timeline

Start
1999-03
Primary completion
2000-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified
Subject Tipranavir Small molecule
Background Delavirdine Small molecule
Background Lamivudine Other / unclassified
Background Stavudine Other / unclassified
Background Zidovudine Small molecule